Eloxx Pharmaceuticals, Inc. (ELOX)

Market Cap	62.61M
Revenue (ttm)	n/a
Net Income	-10.65M
EPS	-2.84
Shares Out	4.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,669
Open	15.92
Previous Close	15.71
Day's Range	14.91 - 16.02
52-Week Range	n/a
Beta	-162,148.90
Analysts	Strong Buy
Price Target	38.25 (+146.62%)
Earnings Date	Aug 12, 2026

About ELOX

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 10
• Stock Exchange: Nasdaq
• Ticker Symbol: ELOX
• Website: https://www.eloxxpharma.com

Analyst Summary

According to 4 analysts, the average rating for ELOX stock is "Strong Buy." The 12-month stock price target is $38.25, which is an increase of 146.62% from the latest price.

Price Target

$38.25

(146.62% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 3, 2026

Data Sources Report a data error